A

Aelis Farma SA
PAR:AELIS

Watchlist Manager
Aelis Farma SA
PAR:AELIS
Watchlist
Price: 2.28 EUR 18.13%
Market Cap: €31.3m

Operating Margin

-1 841.9%
Current
Declining
by 1 401.7%
vs 3-y average of -440.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 841.9%
=
Operating Income
€-8.2m
/
Revenue
€446k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 841.9%
=
Operating Income
€-8.2m
/
Revenue
€446k

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Aelis Farma SA
PAR:AELIS
26.5m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 97% of companies in France
Percentile
3rd
Based on 2 333 companies
3rd percentile
-1 841.9%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Aelis Farma SA
Glance View

Market Cap
31.3m EUR
Industry
Biotechnology

Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

AELIS Intrinsic Value
Not Available
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 841.9%
=
Operating Income
€-8.2m
/
Revenue
€446k
What is Aelis Farma SA's current Operating Margin?

The current Operating Margin for Aelis Farma SA is -1 841.9%, which is below its 3-year median of -440.3%.

How has Operating Margin changed over time?

Over the last 3 years, Aelis Farma SA’s Operating Margin has decreased from -214.3% to -1 841.9%. During this period, it reached a low of -1 841.9% on Jul 30, 2025 and a high of -71.4% on Dec 31, 2023.

Back to Top